Ludzkie koronawirusy - autor: Krzysztof Pyrć z Zakładu Mikrobiologii, Wydział Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagielloński, Kraków

Zastanawiasz się, jak wydać pracę doktorską, habilitacyjną lub monografię? Chcesz dokonać zmian w stylistyce i interpunkcji tekstu naukowego? Nic prostszego! Zaufaj Wydawnictwu Borgis – wydawcy renomowanych książek i czasopism medycznych. Zapewniamy przede wszystkim profesjonalne wsparcie w przygotowaniu pracy, opracowanie dokumentacji oraz druk pracy doktorskiej, magisterskiej, habilitacyjnej. Dzięki nam nie będziesz musiał zajmować się projektowaniem okładki oraz typografią książki.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Nowa Medycyna 6/2002
Aleksandra Kotlińska-Lemieszek, Jacek Łuczak, Ewa Bączyk, Maciej Bączyk
Morfina i inne opioidy w leczeniu bólu nowotworowego. Czym należy kierować się przy wyborze leczenia u pacjentów z bólem trudnym do uśmierzenia
Morphine and other opioids in the treatment of cancer pain. What factors to consider when choosing analgesics in patients with pain difficult to relieve
z Katedry Medycyny Paliatywnej Akademii Medycznej im K. Marcinkowskiego w Poznaniu
Kierownik Katedry: prof. dr hab. med. Jacek Łuczak
Streszczenie
The past 16 years have proved that the WHO principles are a very effective method of cancer pain management. In about 10-15% of patients, however, the pain control is unsatisfactory which might be due to poor response to the analgesics or side effects that limit further dose escalation.
In the article the authors analyse the known patient and opioid factors determining the so-called „responsiveness”. They focus on the methods of improving the effect of pharmacological treatment, such as adequate adjuvant and breakthrough pain management, parenteral treatment, opioid rotation and simultaneous use of two opioids.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. World Health Organization. Cancer pain relief. 2nd edition, with a guide to opioid availability. Geneva 1996. 2. Ventafridda V. et al.: A validation study of the WHO method for cancer pain relief. Cancer, 1987, 59:951-956. 3. Zech D.F. et al.: Validation of World Health Organization guidelines for cancer pain relief: A 10-year prospective study. Pain, 1995, 63:65-76. 4. Portenoy R.K. et al.: The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain, 1990, 43:273-286. 5. Rawal N.: Opiods in acute pain. In: red. Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 247-270. 6. Gutstein H.B., Akil H.: Opioid analgesics. W: Goodman and Gilman. The pharmaceutical basis of therapeutics. Mc Graw Hill Medical Publishing Division 10th Ed. 569-611. 7.Darland T. et al.: Orphanon FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci, 1998, 21 (5):215-221. 8.Henderson G., McKnight A.T.: The orphan opioid receptor and its endogenous ligand- niciceptin/orphanin FQ. Trends Pharmacol Sci., 1997, 18:293-300. 9. Raynor K. et al.: Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol., 1994, 45:330-334. 10. Ross F., Smith M.: The intrinsic antyinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain, 1997, 73:151-157. 11. Rothman R.: Buprenorphine: a rewiev of binding literature. In: Cowan A., Lewis J. (red.): Buprenorphine: combatting drug abuse with unique opioid. Wiley-Liss, New York, 151-163. 12.Budd K.: Buprenorphine: a review. Evidence Based Medicine in Practice (April 2002), Hayward Medical Communications, Newmarket. 13. Hill R.G.: Multiple opioid receptors and their ligands. Frontiers of Pain, 1992, 4:1-4. 14. Corbett A.D. et al.: Selectivity of ligands for opioid receptors. In: Herz A. (red.): Opioids. Springer-Verlag, London 1993, 657-672. 15.Twycross R. et al.: Analgesics. In: Palliative Care Formulary, Radcliffe Medical Press, 2002, 129-202. 16. Woolf C.J., Mannion R.J.: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999, 353:1959-64. 17. Heinricher M.M., Morgan M.M.: Supraspinal Mechanisms of opioid analgesia. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 46-69. 18. Stein C. et al.: Peripheral opioid analgesia: mechanisms and clinical implications. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 96-108. 19. Woolf C., Bromley L.: Pre-emptive analgesia by opioids. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 212-233. 20. Sivilotti L.G. et al.: Morphine selectively depresses the slowest, NMDA-independent component of C-fibre evoked synaptic activity in the rat spinal cord in vitro. Eur. J. Neurosci., 1995, 7:12-18. 21.Dickenson A.H.: Where and how do opioids act? In: Gebhart G.F., Hammond D.L., Jensen T.S.: Proceedings of the 7th World Congress on Pain. Progress in pain research and management. Vol. 2. IASP Press. Seattle, 1994, 525-552. 22. Mao J. et al.: Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain, 1995, 62:259-274. 23. Wiesenfeld-Hallin Z., Xiao-Jun Xu: Opioid-nonopioid interaction. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 131-143. 24. Cesselin F. et al.: Spinal mechanisms of opioid analgesia. In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 70-95. 25. Duttaroy A., Yoburn B.C.: The effect of intrinsic efficacy on opioid tolerance. Anesthesiology, 1995, 82:1226-1236. 26. Sosnowski M., Yaksh T.L.: Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anaesthesiology, 1990, 73:1141-1147. 27. Sanford T.J. et al.: A comparison of morphine, fentanyl, and sufentanil anaesthesia for cardiac surgery: Induction, emergence, and extubation. Anesth. Analg., 1986, 65:159-166. 28. Bilsky E.J. et al.: Competitive and non-competitive NMDA antagonists block the developement of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain, 1996, 68:229-237. 29. Mather L.E., Smith M.: Clinical Pharmacology and Adverse Effects . In: (red.) Stein Ch.: Opioids in pain control. Basic and clinical aspects. Cambridge University Press, 1999, 188-211. 30. Kujawska-Tenner J. i wsp.: Zwalczanie bólów nowotworowych. MZOS, Warszawa 1994. 31. Leppert W. et al.: Tramadol and cancer pain. European Journal of Palliative Care, 2002, 9 (2):49-51. 32. Raffa R.B. et al.: Opioid and non-opioid components indepedently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. Journal of Pharmacology and Therapeutics, 1992, 260:275-285. 33. Poulsen L. et al.: The hypoalgesic effect of tramadol in relation to CYP2D6. Clinical Pharmacology and Therapeutics, 1996, 60:636-644. 34. Lurcott G. et al.: The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesthesia Progress, 1999, 45:154-156. 35. Fromm M. et al.: Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans. Clinical Pharmacology and Therapeutics, 1995, 58:374-382. 36. Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer, 2001, 84:587-593. 37. Boerner U. et al.: The metabolism of morphine and heroin in man. Drug metabolism reviews, 1975, 4(1):39-57. 38. Mazoit J-X. et al.: Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesthesia and Analgesia, 1987, 66:293-298. 39. Sandouk P. et al.: Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine. European Journal of Drug Metabolism and Pharmacology, 1991, 16 (suppl. 3):166-171. 40. Corrupt P. et al.: Morphine-6-glucuronide and morphine-3-glucuronide as a molecular chameleons with unexpected lipophylicity. J. Med. Chem. 1991, 34:1272-1275. 41. Hanna M.H. et al.: Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br. J. Anaesth., 1990, 64:547-550. 42.Woolf T. et al.: Morphine nad morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain, 1995, 62:147-154. 43. Portenoy R.K. et al.: Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology, 1991, 41:1457-61. 44. McQuay H.J. et al.: Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin. Pharmacol. Ther., 1990, 48:236-244. 45. Säwe J. et al.: Kinetics of morphine in patients with renal failure. Lancet, 1985, 211. 46. Peterson G.M. et al.: Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur. J. Clin. Parmacol., 1990, 38:121-124. 47. Portenoy R.K. et al.: Plasma morphine and morphine-6-glucuronide during morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain, 1991, 47:13-19. 48. Faura C.C. et al.: Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain, 1998, 74 (1):43-53. 49. Houde R.W. et al.: Clinical measurement of pain. In: de Stevens G. (eds.): Analgesics. Academic Press, NY, 1965, 75-122. 50. Twycross R.G.: Oral morphine. In: Twycross R.G.: Pain relief in advanced cancer. Churchill Livingstone, 1994, 307-332. 51. Continous Cancer Pain. Durogesic. Fentanyl Transdermal System. Monograph. CMC International Inc., USA 2001. 52. Donner B. et al.: Long-term treatment of cancer pain with transdermal fentanyl. J. Pain. Symptom. Manage., 1998, 15 (3):168-175. 53. Fine P.G. et al.: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain, 1991, 45:149-153. 54. Lewis J.: Clinical pharmacology of buprenorphine in relation to its use as an analgesic. In: Cowan A., Lewis J. (red.): Buprenorphine: combatting drug abuse with unique opioid. Wiley-Liss, New York, 151-163. 55. Radbruch L.: Transtec- Buprenorfina TDS. X Congress on Pain. San Diego, 2002. 56. Pausawasdi S. et al.: The effect of buprenorphine and morphine on intraluminal pressure of the common bile duct. Journal of Medical Association of Thailand, 1985, 76:329-333. 57. Gorman A. et al.: The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters, 1997, 223:5-8. 58. Codd E. et al.: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in nociception. Journal of Pharmacology and Experimental Therapeutics, 1995, 274:1263-1270. 59. Morley J., Makin M.: The use of methadone in cancer pain poorly responsive to other opioids. Pain Rewievs, 1998, 5:51-58. 60. Krajnik M., Żylicz Z.: Metadon w leczeniu bólu nowotworowego. Polska Medycyna Paliatywna, 2002, Nr1, Tom 1:15-22. 61. Nilsson M.I. et al.: Clinical pharmacokinetics of methadone. Acta Anaesthesiol. Scand., 1982, 26 (supl.74):66-69. 62. Farrel A., Rich A.: Analgesic use in patients with renal failure. Eur. J. Palliat. Care, 2000, 7:201-205. 63. Mancini I.L. et al.: Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J. Palliat. Med., 2000, 3:49-56. 64. Heiskanen T., Kalso E.: Controlled-release oxycodone and morphine in cancer related pain. Pain, 1997, 73:37-45. 65. Heiskanen T. et al.: Effects of blocking CYP2D6 on oxycodone. Clinical Pharmacology and Therapeutics, 1998, 64:603-611. 66.Anderson R. et al.: Accuracy in analgesic dosing: Conversion dilemmas. J.Pain Symptom Manage, 2001, 21:397-406. 67. de Stoutz N.D. et al.: Opioid rotation for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage, 1995, 10:378-384. 68. Sjögren P. et al.: Disappearance of morphine-induced hyperalgesia after discontinuing of substitution morphine with other opioid agonists. Pain, 1994, 59:313-316. 69. Vigano A. et al.: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain, 1996, 67:115-119. 70. Ripamonti C. et al.: Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? Journal of Clinical Oncology, 1998, 16 (10): 3216-3221. 71. Osborne R.J. et al.: Morphine and metabolite behaviour after different routes of administrationof the importance of the active metabolite morphine-6-glucutronide. Clin. Pharmacol. Ther., 1990, 47:12-19. 72. Van Dongen R.T.M. et al.: Morphine and morphine glucuronide concentrations in plasma and CSF during long-term administration of oral morphine. Br. J. Pharmacol., 1994, 38:271-273. 73. Gouke C.R. et al.: Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine resistat pain. 1994, 56:145. 74. Tiseo P.J. et al.: Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain, 1995, 61:47-54. 75. Sjögren P. et al.: Myoclonic spasm during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol, Scand., 1993, 37:780-782. 76. Bruera E., Pereira J.: Neuropsychiatric toxicity of opioids. In: Jensen T.S., Turner J.A., Wiesenfeld-Hallin Z.: Proceedings of the 8th World Congress on Pain. Progress in pain research and management. Vol.8. IASP Press. Seattle, 1997, 717-738. 77. Krajnik M., Żylicz Z.: Topical opioids. fact or fiction? Progress in Pall. Med., 1997, 5 (3):101-106. 78. Portenoy R.K. et al.: Breakthrough pain: definition, prevalence and characteristics. Pain, 1990, 41:273-281. 79. Portenoy R.K. et al.: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain, 1999, 81:129-134. 80. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer, 2002, 95 (1):203-208. 81. The essential adjuvant analgesics for neuropathic pain. Cancer Pain Release, 2002, Vol.15, No2:1-4. 82. Oshima E. et al.: Continuous subcutaneous injection of ketamine for cancer pain. Can. J. Anaesth., 1990, 37:385-92. 83. Mercadante S. et al.: Long-term ketamine subcutaneous contineous infusion in neuropathic cancer pain. J. Pain Symptom Manage, 1995, 10 (7):564-568. 84. Broadley K.E. et al.: Ketamine injection used orally. Palliative Medicine, 1996, 10:247-250. 85. Mercadante S. etal.: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. Journal of Pain and Symptom Management, 2000, 20 (4):246-252. 86. Łuczak J. et al.: The role of ketamine, an NMDA receptor antagonist, in the management of pain. Progress in Palliative Care, 1995, 3:127-134. 87. Kotlińska-Lemieszek A. et al.: Miejsce ketaminy w leczeniu bólów nowotworowych. Wyniki 12-letnich obserwacji. II Międzynarodowe Sympozjum. Postępy w leczeniu bólu. Zakopane, 25-28 września 2002. Ból, 2002, 3, 3:43.
Nowa Medycyna 6/2002
Strona internetowa czasopisma Nowa Medycyna